Is CAR-T safe for early-stage patients?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with a reminder that my colleague Ed Silverman is hosting a discussion today about the long-awaited arrival of Humira biosimilars and all they portend for drug costs, insurance coverage, and pharma revenues. Sign up to tune in here.

The need-to-know this morning

• AstraZeneca said it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.
• The U.K.’s cost-effectiveness watchdog said it is not yet recommending Vertex Pharmaceutical’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

Small studies offer hope for treating brain cancer

Data from a handful of patients with a deadly, incurable form of brain cancer suggest cell therapy could become a powerful treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In